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To evaluate clinical and molecular predictors of the risk of mortality in people with neurofibromatosis 2 (NF2),
we analyzed the mortality experience of 368 patients from 261 families in the United Kingdom NF2 registry, using
the Cox proportional-hazards model and the jackknife method. Age at diagnosis, intracranial meningiomas, and
type of treatment center were informative predictors of the risk of mortality. In Cox models, the relative risk of
mortality increased 1.13-fold per year decrease in age at diagnosis (95% confidence interval [CI] 1.08–1.18) and
was 2.51-fold greater in people with meningiomas compared with those without meningiomas (95% CI 1.38–
4.57). The relative risk of mortality in patients treated at specialty centers was 0.34 compared with those treated
at nonspecialty centers (95% CI 0.12–0.98). In a separate model, the relative risk of mortality in people with
constitutional NF2 missense mutations was very low compared with those with other types of mutations (nonsense
or frameshift mutations, splice-site mutations, and large deletions), but the CI could not be well quantified because
there was only one death among people with missense mutations. We conclude that age at diagnosis, the strongest
single predictor of the risk of mortality, is a useful index for patient counseling and clinical management (as are
intracranial meningiomas). To ensure optimal care, we recommend that people with NF2 be referred to specialty
treatment centers.
Introduction
Neurofibromatosis 2 (NF2 [MIM 101000]) is an auto-
somal dominant disorder that is caused by inactivating
mutations or loss of both alleles of the NF2 tumor-sup-
pressor gene (Rouleau et al. 1993; Trofatter et al. 1993).
Vestibular schwannomas (VSs), intracranial menin-
giomas, spinal tumors, peripheral nerve tumors, and pre-
senile lens opacities are common in NF2 (Evans et al.
1992a; Parry et al. 1994; Mautner et al. 1996). VSs
occur in ∼95% of adults with NF2 (bilateral VSs are
pathognomonic for NF2), meningiomas in ∼50%, and
presenile lens opacities in ∼60%–80%. Spinal tumors
occur in ∼90% of people with NF2, although only 30%
of these people have symptomatic spinal tumors (Maut-
ner et al. 1995).
Cross-sectional studies of genotype-phenotype cor-
relations in NF2 have found that, in general, consti-
tutional nonsense and frameshift NF2 mutations are
associated with severe disease; missense mutations, in-
frame deletions, and large deletions with mild disease;
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and splice-site mutations are associated with variable
disease severity (Me´rel et al. 1995; Kluwe et al. 1996,
1998; Parry et al. 1996; Ruttledge et al. 1996; Evans
et al. 1998a). There have been few longitudinal studies
of NF2, because of the rarity of the disease (Evans et
al. 1992b; Antinheimo et al. 2000). In two recent short-
term longitudinal studies of the predictors of VS growth
rates in NF2, VS growth rates tended to be higher in
people with a younger age at onset or diagnosis of NF2,
but they were highly variable, even among affected
relatives of similar ages in a single family (Baser et al.
2002; Mautner et al. 2002). As yet, there have not been
any longitudinal studies of other common tumors in
NF2, such as intracranial meningiomas or spinal tu-
mors, which also cause considerable morbidity (Evans
et al. 2000).
NF2 is a chronic disease in which life expectancy,
although often shortened, is lengthy. Short-term studies
of the growth rates of NF2-associated tumors, especially
studies of a single tumor type, do not reflect the total
disease burden of NF2 or the efficacy of treatment as
well as do long-term studies that utilize a more inclusive
measure of health, such as mortality. Evans et al. (1992a)
found that mean actuarial survival in people with NF2
was 62 years, and Parry et al. (1994) reported that broad
categories of NF2 disease severity (mild, intermediate,
and severe) were correlated with age at death. Neither
of these studies evaluated specific clinical or molecular
characteristics as potential predictors of the risk of mor-
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tality. In the present study, we evaluated clinical and
molecular predictors of the risk of mortality in a large
series of people with NF2.
Subjects and Methods
Patient Population
The United Kingdom NF2 registry is based in the
Department of Medical Genetics, St. Mary’s Hospital,
Manchester. People are ascertained by contacting neu-
rosurgeons, otolaryngologists, neurologists, pediatri-
cians, dermatologists, and geneticists throughout the
United Kingdom, and the collection is augmented in
the North West Region by the Regional Cancer Reg-
istry. The present study was subject to continuing
ethics committee evaluation, and participants gave in-
formed consent.
As of February 15, 2002, the registry had 425 people
from 282 families. For the present study, we excluded
three groups of people: (1) We excluded known somatic
mosaics ( ; shown to be mosaic at the molecularNp 17
level). Almost all reported NF2 somatic mosaics have
mild disease, despite having nonsense or frameshift mu-
tations that typically cause severe disease in classical
NF2 (Evans et al. 1998b; Kluwe and Mautner 1998).
(2) We excluded people who were born before 1930
( ). All such individuals in the United KingdomNp 34
NF2 registry were identified through younger affected
relatives. The pre-1930 group was excluded because it
did not meet the proportional-hazards assumption for
the Cox analysis. Specifically, type of treatment center
and meningiomas did not predict the risk of mortality
in people who were born before 1930, in contrast to
those born after 1930. (3) We excluded people with miss-
ing information on either age at diagnosis ( ) orNp 2
presence of intracranial meningiomas ( ), twoNp 4
covariates that are necessary for analysis of the risk
of mortality.
The resultant study group had 368 people from 261
families, all of whom met the Manchester clinical di-
agnostic criteria for NF2 (Evans et al. 1992a) or had
identified constitutional NF2 mutations. The distribu-
tion of the number of affected family members was 206
families with one affected member, 27 families with two
affected members, 15 families with three affected mem-
bers, 7 families with four affected members, 3 families
with five affected members, 1 family with six affected
members, and 2 families with seven affected members.
There were 43 two-generation families and 9 three-gen-
eration families. There were 223 people with new mu-
tations (individuals with sporadic disease and founders)
and 145 people with inherited mutations.
NF2 Mutation Analysis
Genomic DNA samples prepared from peripheral
leukocytes were amplified with primers for all 17 exons
of the NF2 gene, and screening was performed for con-
stitutional NF2 mutations, using SSCP analysis, as de-
scribed elsewhere (Evans et al. 1998a).
Statistical Analysis
Potential predictors of the risk of mortality were first
assessed using univariate Kaplan-Meier survival curves.
The covariates examined were age at onset of symptoms,
age at diagnosis, sex, type of constitutionalNF2mutation,
inheritance (new mutation or inherited case), generation
(in the 52 multigeneration families), presence and number
of each type of NF2 nervous system tumor (VSs, intra-
cranial meningiomas, spinal tumors, and peripheral nerve
tumors), lens opacities, number of surgical operations,
calendar year of diagnosis, and type of treatment center
(specialty or nonspecialty). The specialty treatment cen-
ters were hospitals withNF2 specialistmanagement teams
(Manchester Royal Infirmary, Addenbrooke’s Hospital
[Cambridge], and Royal London Hospital).
The number of tumors at diagnosis was used because
data from serial examinations were not routinely avail-
able. A potential concern about this choice is that im-
aging done prior to the late 1980s (i.e., with comput-
erized tomography) may be of poorer quality and may
tend to underestimate the number of tumors, in com-
parison with imaging done more recently (i.e., withmag-
netic resonance imaging). Several lines of evidence in-
dicate that this potential bias is negligible in people with
meningiomas or spinal tumors. The number of menin-
giomas did not vary significantly by calendar year of
diagnosis ( ), after adjustment, using linear re-Pp .95
gression, for age at diagnosis of the first intracranial
meningioma. Some people present with VSs but later
develop intracranial meningiomas or have meningiomas
that may not have been detected at presentation because
of suboptimal imaging. Of the 136 people with both VSs
and meningiomas, 25% were diagnosed with menin-
giomas after their VSs were diagnosed, and the median
time between detection of VSs and meningiomas in these
people was only four years. Some people may not have
spinal imaging early in the course of their disease, but
the median time between initial assessment and diag-
nosis of spinal tumors was only one year.
The presentation of NF2 is different in adults than in
children, whose initial sign or symptom is often unre-
lated to VSs (Mautner et al. 1993; MacCollin andMaut-
ner 1998). For this reason, interactions between age at
diagnosis and number of each type of nervous system
tumor were evaluated in the Cox models; none of these
interactions were statistically significant. Age at onset of
symptoms and age at diagnosis were highly correlated
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Table 1
Characteristics of 368 People with NF2 in the Study Population
Characteristic No. %
Vital status:a
Alive 295 80.2
Dead 73 19.8
Sex:
Female 191 51.9
Male 177 48.1
Inheritance:
New mutation 223 60.6
Inherited mutation 145 39.4
Age at onset of symptoms (years):
1–19 153 41.8
20–39 155 42.3
40 34 9.3
Asymptomatic 24 6.6
Age at diagnosis (years):
1–19 116 31.5
20–39 186 50.6
40 66 17.9
VS:
None 23 6.3
Unilateral 33 9.0
Bilateral 310 84.7
Intracranial meningiomas:
Absent 203 55.2
Present 165 44.8
Type of constitutional NF2 mutation:b
Nonsense 43 13.5
Frameshift deletion 27 8.5
Frameshift insertion 10 3.1
Splice donor site 19 6.0
Splice acceptor site 36 11.3
Missense 22 6.9
Large deletion 47 14.8
Not identified 114 35.8
Type of treatment center:
Nonspecialty 259 70.4
Specialty 109 29.6
a As of February 15, 2002.
b Frequency of mutations in 318 people from 216 families that were
screened for constitutional NF2 mutations (molecular model).
Figure 1 Kaplan-Meier survival curve (log-rank test): age at
diagnosis ( ).P ! .0001
( , ); age at diagnosis was used in the2r p .63 P ! .001
analysis because tumor burden was usually first evalu-
ated at this time. Age at diagnosis and calendar year of
diagnosis were not highly correlated ( ,2r p .01 Pp
). Initial data analyses included some separate anal-.15
yses for people with new mutations and those with in-
herited disease, but the two groups were similar in sur-
vival rates (as shown by Kaplan-Meier curves), so people
with new mutations and those with inherited disease
were combined in further analyses. Proband/nonpro-
band status and new mutation/inherited mutation status
were highly correlated, so proband status was not con-
sidered further as a covariate.
The covariates that were most highly associated with
the risk of mortality in single-predictor Cox propor-
tional hazards models were added sequentially to a mul-
tiple-predictor Cox model until there was only a minor
decrease in the log partial likelihood. The log partial
likelihood, an output-summary value of Cox regression
analysis, using S-Plus (Venables and Ripley 1997, is con-
sidered to be an indicator of how well a set of potential
predictors explain the variation in survival times; be-
cause of the dependence within families, it is not the
actual partial likelihood. We constructed two Cox mod-
els, one without and one with information on the type
of constitutionalNF2mutation. The resulting two mod-
els are called the “clinical model” and the “molecular
model.” The mutation type covariate is categorical and
is coded as several binary variables. These variables were
indicators of splice-site mutations, missense mutations,
large deletions, and unidentified mutations, each com-
pared with nonsense or frameshift mutations. The cat-
egory of unidentified mutations can include different
types of mutations but was treated as a single category
for the purpose of this analysis. The molecular model
excluded 46 people who had not been screened for con-
stitutional NF2 mutations, 2 people with in-frame de-
letions, and 2 people with chromosomal translocations.
The Cox model assumes independence of families and
independence of members within families. The latter part
of this assumption is violated when there is correlation
between family members. When the data are positively
correlated, the SEs of parameters estimated under the
assumption of independence will tend to be too small,
which could lead to an erroneous conclusion that an
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Figure 2 Kaplan-Meier survival curve (log-rank test): intra-
cranial meningiomas ( ).Pp .0003
Figure 3 Kaplan-Meier survival curve (log-rank test): type
of constitutional NF2 mutation ( ).Pp .0020
effect is important. To surmount this problem for the
Cox models, the delete-one jackknife method, with fam-
ily as the unit, was used to determine the adjusted pa-
rameter estimates and their SEs in the Cox model. The
jackknife is a standard statistical method that is com-
monly used to correct for bias in parameter estimates
and to provide SEs in nonstandard sampling situations
(Mosteller and Tukey 1977).
In addition to fitting Cox models, we fitted log-normal
regression models (regressing log survival on sets of pre-
dictor variables), using the S-Plus function called “surv-
reg.” The results are qualitatively the same as those of
the Cox model. To assess the amount of intrafamilial
correlation, r, the simplest approach is to add familial
dependence to the log-normal regression model and use
a multivariate log-normal distribution for the vector of
log survival for each family. The simplest dependence
structure is exchangeable dependence; this assumes a
common correlation for each pair of family members.
This dependence obtains from a random-effects model
with a common family effect plus individual effects.
In notation, the model is ,′logY p b  b x  F  Eij 0 ij i ij
where i is the index for families, j is the index for mem-
bers within a family, Y is the survival time, xij is a vector
of covariates, Fis are independent family effects that have
a normal distribution with mean 0 and variance , Eijs
2jF
are independent individual effects that have a normal
distribution with mean 0 and variance . The ratio of2jE
variances between and within families is , and2 2vp j /jF E
the intrafamilial correlation is . For a fam-rp v/(1 v)
ily with left-censored Yij, the likelihood contribution in-
volves a multivariate normal-rectangle probability; for
the random-effects model given above, the rectangle
probability can be computed as a one-dimensional nu-
merical integral. The log-likelihood can be numerically
maximized with a quasi-Newton routine, to obtainmax-
imum-likelihood estimates of the parameters.
Results
The characteristics of the study population are presented
in table 1. The mean  SE age at onset of symptoms
was 22  1 years, and the mean age at diagnosis was
27  1 years. The median length of follow-up from
initial clinical evaluation was 7 years (range 0–37 years).
Ninety-eight percent of people were diagnosed after
1970. Ninety-four percent of people had VSs, and 45%
had intracranial meningiomas. Age at diagnosis did not
vary significantly by meningioma status (presence or ab-
sence of intracranial meningiomas) (mean  SE 28 
1 years with meningiomas absent, 27  1 years with
meningiomas present). Constitutional NF2 mutations
were identified in 120 (56%) of the 216 families that
were screened for mutations. Seventy-four (20%) of the
368 people died during follow-up: 51 of tumor burden,
14 of complications in the immediate postoperative pe-
riod, 3 of malignancies arising from an NF2-associated
tumor, 2 each of traffic accidents and suicide, and 1 each
of a fall due to NF2-associated imbalance and a myo-
cardial infarction.
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Figure 4 Kaplan-Meier survival curve (log-rank test): type
of treatment center ( ).Pp .0001
Table 2
Parameter Estimates and SEs for the Clinical Model (261 Families with NF2)
Variable b SEb RR 95% CIRR
Age at diagnosis (per year decrease) .12 .02 1.13 1.08–1.18
Intracranial meningiomas (present vs. absent) .92 .31 2.51 1.38–4.57
Type of treatment center (specialty vs. nonspecialty) 1.07 .54 .34 .12–.98
In single-predictor Cox models, five covariates were
at least moderately associated with the risk of mortality:
age at diagnosis, intracranial meningioma status, type
of constitutional NF2 mutation, type of treatment cen-
ter, and calendar year of diagnosis. Kaplan-Meier sur-
vival curves are presented in figures 1–4. These covar-
iates were included sequentially in multiple-predictor
Cox models.
In the clinical model, the best multiple-predictor
Cox model had three covariates, which were, in order
of importance, age at diagnosis, type of treatment
center, and meningioma status. The relative risk (RR)
of mortality increased 1.13-fold per year decrease in
age at diagnosis (95% CI 1.08–1.18) and was 2.51-fold
greater in people with meningiomas compared with
those without meningiomas (95% CI 1.38–4.57). The
RR of mortality in people treated at specialty centers
was 0.34 compared with those treated at nonspecialty
centers (95% CI 0.12–0.98). The coefficients for these
covariates were stable across Cox models with different
sets of predictors. See table 2 for the summary of this
Cox model; SEs were based on the jackknife method
with the family as the sampling unit. Calendar year of
diagnosis had little additional predictive value after age
at diagnosis was included. In a separate model that in-
cluded the covariates of age at diagnosis and type of
treatment center but substituted number of menin-
giomas for presence of meningiomas, the RR of mor-
tality did not significantly increase with increasing num-
ber of meningiomas; however, each group had relatively
few people (61 people with one meningioma, 63 with
two or three meningiomas, and 35 with more than three
meningiomas).
In the molecular model, the best multiple-predictor
Cox model had three covariates, which were, in order
of importance, age at diagnosis, type of treatment cen-
ter, and mutation type. Meningioma status had little
additional predictive value after these three variables
were in the model. See table 3 for a summary of this
Cox model; the bs for the four mutation types are rel-
ative to nonsense or frameshift mutations. The main
conclusion is that people with missense mutations have
a much lower risk of mortality than do people with any
of the other types of mutations. This can be seen from
the number of deaths among people with the five types
of mutations: 15 of 80 for nonsense or frameshift mu-
tations, 15 of 55 for splice-site mutations, 9 of 47 for
large deletions, 19 of 114 for unidentified mutations,
and 1 of 22 for missense mutations. Because there is
only one death in the missense mutation group, the
jackknife does not provide a reliable SE estimate for b
for the missense mutation group; the data in table 3 for
this variable are based on the omission of two jackknife
outliers.
For the random-effects model for log survival time,
the covariates of age at diagnosis, type of treatment
center, and presence of meningiomas were fitted. The
summary of the parameter estimates is given in table
4. The estimated intrafamilial correlation is 0.56p
, with a wide 95% CI of 0.0–0.73. The1.25/(1 1.25)
data set is small and has a high censoring rate, so the
intrafamilial correlation cannot be estimated precisely.
However, the random-effects model appears to adapt
well to censored data.
Discussion
In the present study, we found that four covariates were
informative predictors of the risk of mortality in people
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Table 3
Parameter Estimates and SEs for the Molecular Model (216 Families with NF2)
Variable b SEb RR 95% CIRR
Age at diagnosis (per year decrease) .14 .03 1.15 1.09–1.21
Type of treatment center (specialty vs. nonspecialty) 1.21 .63 .30 .08–1.05
Type of constitutional NF2 mutation (vs. nonsense or frameshift):
Splice-site .22 .67 1.24 .33–4.70
Missense 2.49 .51 .08 .03–.23
Large deletion .29 .49 .75 .28–2.00
Unidentified .31 .51 .73 .26–2.00
Table 4
Parameter Estimates and SEs for the Random-Effects Model for Log
Survival (261 Families with NF2)
Variable Estimate SE
jE .18 .03
v 1.25 .73
b0 3.15 .06
Age at diagnosis (per year increase) .23 .02
Intracranial meningiomas (present vs. absent) .07 .04
Type of treatment center (specialty vs. nonspecialty) .21 .06
with NF2. The risk of mortality increasedwith decreasing
age at diagnosis and was greater in people with intracra-
nial meningiomas compared with those without menin-
giomas. The risk of mortality was lower in people with
constitutionalNF2missense mutations than in those with
other types of mutations and in people who were treated
at specialty centers comparedwith thosewhowere treated
at nonspecialty centers. The simplicity of age at diagnosis,
by far the strongest single predictor of risk of mortality
in NF2, makes it a useful index for patient counseling
and clinical management; intracranial meningiomas are
also useful in this regard. A possible reason for the higher
risk of mortality in people with NF2 who are diagnosed
at younger ages is that tumor growth is generally more
rapid in these patients (Baser et al. 2002; Mautner et al.
2002), perhaps because of a higher rate of somatic cell
growth or a larger proportion of growing cells in young
people. Age at onset (which is highly correlated with age
at diagnosis) and number of non-VS intracranial tumors
are key indices of NF2 disease severity (Parry et al. 1994).
Other covariates, such as sex, inheritance, and year of
diagnosis, were not as useful predictors of the risk of
mortality. However, as more information is collected on
people with NF2 in the future, the assessment of the risk
of mortality should be repeated with these covariates,
since it is possible that the present data are insufficient to
detect some associations.
In the clinical model, the empirical importance of
the type of treatment center is comparable to that of
meningioma status. The effect of treatment in specialty
centers is not due to marked differences in the char-
acteristics of people who were seen at specialty and
nonspecialty treatment centers. New mutations in these
two groups were similar with respect to age at onset of
symptoms, age at diagnosis, and prevalence of menin-
giomas. Similar proportions of people with inherited
mutations were treated at specialty and nonspecialty
centers.
In all likelihood, a major cause of the lower risk of
mortality in people with NF2 who are treated in spe-
cialty centers is the increasing rate of favorable opera-
tive outcomes and the decreasing rate of postoperative
complications with increasing surgical experience.
When new surgical teams are being trained for VS sur-
gery, there are clear trends, as the number of surgeries
increases, toward improved postoperative preservation
of facial nerve function, complete resection rate, and
hearing preservation, as well as a lowered incidence of
serious complications, such as cerebrospinal fluid leaks
(Buchman et al. 1996;Welling et al. 1999). In Denmark,
decentralized VS neurosurgery was associated with very
high rates of perioperative mortality (8.5%) and serious
surgical complications (35.6%) (Charabi et al. 1992).
People with benign meningioma who are treated in ac-
ademic hospitals have significantly lower mortality, af-
ter adjustment for other risk factors, than do those who
are treated in community hospitals (McCarthy et al.
1998). In addition to more extensive surgical experi-
ence, specialty centers have coordinated expertise in the
multiple clinical specialties that are needed to properly
diagnose NF2 and to treat affected individuals and their
at-risk family members (Evans et al. 1993; Jackler 1998).
To ensure optimal care, we recommend that people with
NF2 be referred to specialty centers.
Almost all of the people in this study were diagnosed
after 1970. During the last three decades, there have
been considerable improvements in neuroimaging tech-
niques that have permitted earlier detection of small
tumors. In combination with improvements in neuro-
surgical treatments, this has led to better clinical man-
agement and a much greater incentive to diagnose VSs
and NF2. The noninclusion of the more recent years of
diagnosis in the multiple-predictor Cox models does not
suggest that improvements in clinical care lack benefit.
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In all likelihood, insufficient time has elapsed for such
benefit to be reflected in decreased mortality. In ad-
dition, the benefits from incremental improvements
in clinical care throughout the post-1970 era may be
more subtle, with respect to risk of mortality, than those
that occurred with the advent of computerized tomog-
raphy scanning in the early 1970s.
Of the people withNF2who have access to treatment,
relatively few die of their VSs. In the modern era of
improved microsurgical techniques, operative mortality
in specialized neuro-otology treatment centers is 1%,
and recurrence rates are nil when the entire VS and
vestibular nerves are excised. Intracranial meningiomas
and spinal tumors are common in NF2, and these re-
current tumors often require repeated surgeries. There
is considerable pre- and postoperative morbidity due to
seizures, paralysis, wasting, pneumonia, and accidents
associated with meningiomas and spinal tumors (Evans
et al. 2000).
In the molecular model, the risk of mortality appeared
to be much lower in people with missense mutations
than in those with other types of mutations. Experi-
mental studies have suggested possible mechanisms
through which constitutional NF2 missense mutations
cause milder disease than do nonsense or frameshift
NF2 mutations. Missense mutations produce an NF2
protein (termed “merlin” or “schwannomin”) that is
stable but defective in negative growth regulation,
whereas nonsense mutations do not produce stable pro-
tein (Gutmann et al. 1998). Naturally occurring mis-
sense mutations have reduced, but not absent, activity
of the merlin-binding protein bII-spectrin (Scoles et al.
1998).
Since NF2 mutation type is strongly associated with
age at diagnosis in cross-sectional studies, a logical ques-
tion is why age at diagnosis is more strongly associated
than the type of NF2 mutation with the risk of mor-
tality. Age at diagnosis may be more strongly associated
because both age at diagnosis and age at death reflect
a composite of disease-influencing factors, whereas mu-
tation type is only one of these factors. Other factors
are the stochastic loss of the second NF2 allele (Baser
et al. 1996) and putative modifying genes (Bruder et al.
1999a, 1999b).
Constitutional NF2 mutations that are not found by
SSCP could be mutations in the 3′ or 5′ UTRs, the pro-
moter region, or untranscribed transcriptional control
elements; intronic mutations that are not covered by
SSCP primers; large deletions, insertions, or other re-
arrangements; or mutations in patients who are somatic
mosaics (Zucman-Rossi et al. 1998). Other epigenetic
events (i.e., methylation) could result in loss of NF2
expression (Kino et al. 2001). There is no evidence for
locus heterogeneity in NF2 (Narod et al. 1992). In 60
United Kingdom families that have people with NF2 in
two or more generations, all families have linkage to
NF2, and NF2 mutations have been identified in all but
six families (D.G.R.E., unpublished data).
Approximately 20% of NF2 new mutations are
thought to be somatic mosaics, and almost all have
mild disease, despite having constitutional nonsense
or frameshiftNF2mutations (Evans et al. 1998b; Kluwe
and Mautner 1998). We excluded known somatic mo-
saics from the analysis, and, although some somatic
mosaics probably were not detected, the resultant bias
is likely to be minor. Among the 187 people with new
mutations who underwent molecular screening, path-
ogenic NF2 mutations were not identified in 88. Sixty-
eight of these people with new mutations were 20
years of age at the onset of symptoms, or they had two
or more meningiomas or four or more spinal tumors.
These people are unlikely to be mosaic, because they
have severe disease. The remaining 20 people with new
mutations had mild disease. If 20% of them were mo-
saic, then we failed to identify only four mosaic indi-
viduals in the screened group.
In summary, the strongest single predictor of the risk
of mortality in NF2 is age at diagnosis, which is a useful
index for patient counseling and clinical management,
as is meningioma status. People with constitutionalNF2
missense mutations appear to have a much lower risk
of mortality than do those with other types of mu-
tations. Our finding that people with NF2 who are
treated at specialty centers have a lower risk of mor-
tality is consistent with studies of unilateral sporadic
VS, in which surgical outcomes were improved and op-
erative complications were reduced in proportion to in-
creasing surgical experience. To ensure optimal care, we
recommend that people with NF2 be referred to spe-
cialty treatment centers.
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